Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis.
about
Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challengeAttenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive ratsPirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failurePharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future PerspectivesNintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosisManagement of fibrosis: the mesenchymal stromal cells breakthroughFibroblasts and myofibroblasts in wound healingUpdate on therapeutic management of idiopathic pulmonary fibrosisReversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic ratsPirfenidone nanoparticles improve corneal wound healing and prevent scarring following alkali burnLower expression of platelet derived growth factor is associated with better overall survival rate of patients with idiopathic nonspecific interstitial pneumoniaPirfenidone normalizes the tumor microenvironment to improve chemotherapyEffects of Pirfenidone and Collagen-Polyvinylpyrrolidone on Macroscopic and Microscopic Changes, TGF-β1 Expression, and Collagen Deposition in an Experimental Model of Tracheal Wound Healing.Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription.A new hypothesis about the origin of uterine fibroids based on gene expression profiling with microarraysIn vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion.Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin BPirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells.New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosisExperimental models of duchenne muscular dystrophy: relationship with cardiovascular disease.Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C.Atrial fibrosis and the mechanisms of atrial fibrillationThe multifaceted role of pirfenidone and its novel targets.Pirfenidone: an anti-fibrotic therapy for progressive kidney disease.Novel therapeutic approaches for pulmonary fibrosis.Pirfenidone for diabetic nephropathy.Pirfenidone gel in patients with localized scleroderma: a phase II study.Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids.Pharmacokinetics of pirfenidone after topical administration in rabbit eye.The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial.Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatmentStructural and functional correlations in a large animal model of bleomycin-induced pulmonary fibrosis.Oral pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study.Pirfenidone inhibits transforming growth factor-β1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19.Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future.Current and novel drug therapies for idiopathic pulmonary fibrosis.Dapson in heterocyclic chemistry, part VIII: synthesis, molecular docking and anticancer activity of some novel sulfonylbiscompounds carrying biologically active 1,3-dihydropyridine, chromene and chromenopyridine moieties.The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis.Pirfenidone inhibits fibrosis in foreign body reaction after glaucoma drainage device implantation
P2860
Q24652737-6B15D880-13F9-4A35-803B-DAB752ECE182Q24673267-EF79B137-D232-4164-8A69-9D3C76E2FAB7Q24684669-7AC5D60F-F034-4B22-83B0-1A68E6854BD1Q26771309-F818A279-4203-4F4B-A150-ABF11C09C884Q26783169-3408C016-2888-466E-BFC8-812CD42B03B2Q26827231-BE43221C-C4D7-4808-8F1E-9717A748BC74Q26866509-C4C18086-FA5C-4175-A038-58A54474E22AQ28083944-1E573F54-9DE7-4827-B81C-7322DE4E95D4Q28367881-99A46821-1471-4449-9CCE-7909A338ECC5Q28535107-2771C8AE-60CE-49E3-BD58-1EADFBBBD4ECQ33571383-3B07A740-3C47-4B3D-9AA3-CC4F828C2565Q33648546-A48F9AAC-6503-416D-A622-501E4C816F78Q33726417-E438F6FF-3FB6-48AB-8A23-C98D59BC7D51Q33840143-31E2CE99-FADD-4163-B9C1-845D96278C23Q34086320-4A3A1594-3E77-4D19-82FF-8E26E5C22323Q34088175-3499D9E7-8CCA-4042-9338-6DB7F64D8BC2Q34123201-1AC3A369-5A04-40C4-B687-997B6DEB1BB0Q34303074-BD1D9BDD-7E9D-4452-862D-0B3389BED415Q34432217-92E4151F-B718-4EF7-AC84-4CF5ADD0A628Q34503157-78FA5ED1-3469-4B2E-970F-7F8A73B6E2FBQ34508301-F5EB1CA2-C8D5-4DBF-9224-38674752862BQ34537906-7CBF4D20-F34D-4A59-9746-7E45F22B7C38Q34576855-CBDC3D8A-6EB7-4F9F-B3EB-527AD5D51C39Q34623073-B2B4A10F-1F1F-4917-B208-94B675B18726Q34680788-2DED0721-6A96-41B7-A6EF-20570078C24CQ34903224-8177C4A8-81EF-48A0-A98C-A67BBDA97C2EQ35012444-BD5D1F13-91A2-4D78-9D32-3E72D9D146B1Q35025056-DB7ECA73-CDFA-4E5B-8E98-B18064A258A4Q35153367-E1CFEEC9-5747-405A-BE18-2FA3B3284EEBQ35175331-EFE3FEFE-01FE-427A-90A6-D6EF40994F5FQ35177613-AE6C05C6-D2D0-456E-A859-056C7D197EEFQ35551942-FE1A3CCB-5611-4E65-B4D2-C6F909EDFE73Q35728036-2CC5F377-537B-4E21-B4C7-05348B9D19F2Q35840642-516D8ADA-C46F-46F2-8F43-21D5854A38B7Q35919077-4DA06FF1-561A-4A98-A3C9-0BB66F6A19B7Q36264068-E814531C-BBB9-4661-AE4A-30B4CE334258Q36294959-CCD395FE-16F2-47C5-A747-0D71871ED168Q36527362-238B63D5-3537-444A-A86F-62083A759054Q36813946-26B94C05-DB95-4BC5-81A2-8E5E2AE499B9Q36826817-D51AD7CD-AC14-4FAF-84D0-B228814F492C
P2860
Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Effects of pirfenidone on tran ...... amster model of lung fibrosis.
@en
type
label
Effects of pirfenidone on tran ...... amster model of lung fibrosis.
@en
prefLabel
Effects of pirfenidone on tran ...... amster model of lung fibrosis.
@en
P2093
P1476
Effects of pirfenidone on tran ...... amster model of lung fibrosis.
@en
P2093
Gurujeyalakshmi G
P304
P407
P577
1999-10-01T00:00:00Z